tiprankstipranks
ENDRA Life Sciences Inc (NDRA)
NASDAQ:NDRA
US Market

ENDRA Life Sciences (NDRA) Income Statement

575 Followers

ENDRA Life Sciences Income Statement

Last quarter (Q1 2024), ENDRA Life Sciences's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, ENDRA Life Sciences's net income was $-2.78M. See ENDRA Life Sciences’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
-----$ 0.00
Gross Profit
----$ 0.00$ 0.00
Operating Expense
$ 11.84M$ 10.52M$ 13.16M$ 11.50M$ 11.50M$ 10.84M
Operating Income
$ -11.84M$ -10.52M$ -13.16M$ -11.50M$ -11.50M$ -10.84M
Net Non Operating Interest Income Expense
----$ -232.43K$ -2.36M
Other Income Expense
$ -23.39K$ -460.49K$ 21.53K$ 471.22K$ 8.84K$ -106.90K
Pretax Income
$ -11.38M$ -10.06M$ -13.18M$ -11.97M$ -11.73M$ -13.31M
Tax Provision
----$ 0.00$ 0.00
Earnings From Equity Interest Net Of Tax
---$ -121.07K--
Net Income Common Stockholders
$ -11.38M$ -10.06M$ -13.18M$ -11.97M$ -12.12M$ -17.53M
Basic EPS
--$ -4.56$ -5.60$ -0.63$ -2.34
Diluted EPS
--$ -4.56$ -5.60$ -0.63$ -2.34
Basic Average Shares
--$ 2.89M$ 2.05M$ 19.19M$ 7.50M
Diluted Average Shares
--$ 2.89M$ 2.05M$ 19.19M$ 7.50M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 11.84M$ 10.52M$ 13.16M$ 11.50M$ 11.50M$ 10.84M
Net Income From Continuing And Discontinued Operation
$ -11.38M$ -10.06M$ -13.18M$ -11.97M$ -11.73M$ -13.31M
Normalized Income
$ -7.66M$ -7.95M$ -10.41M-$ -11.73M$ -13.31M
Interest Expense
----$ 232.43K$ 2.36M
EBIT
$ -11.39M$ -10.06M$ -13.18M$ -11.97M$ -11.49M$ -10.95M
EBITDA
$ -11.12M$ -9.78M$ -12.94M$ -11.75M$ -11.33M$ -10.84M
Currency in USD

ENDRA Life Sciences Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis